Gland Pharma Limited has officially notified the stock exchanges about an upcoming board meeting scheduled for January 28, 2026, where directors will review and approve the company's third quarter financial performance for FY26. The pharmaceutical company submitted formal intimation letters to both BSE Limited and National Stock Exchange of India Limited regarding this regulatory requirement under SEBI guidelines.

Board Meeting Details

The board meeting agenda focuses on approving unaudited financial statements covering two distinct reporting periods. Directors will examine both standalone and consolidated financial results, providing comprehensive insights into the company's operational and subsidiary performance during the specified timeframes.

Trading Window Restrictions

Gland Pharma has implemented mandatory trading window closures in compliance with SEBI insider trading regulations. The company previously announced these restrictions to prevent any potential misuse of unpublished price-sensitive information during the financial results preparation period.

Investor Engagement Activities

The pharmaceutical manufacturer has arranged stakeholder communication sessions to discuss quarterly performance with market participants. Company management will conduct detailed presentations covering financial metrics, operational highlights, and business developments during the reporting quarter.

• Earnings Call Date: Wednesday, January 28, 2026
• Scheduled Time: 18:30 Hours (Indian Standard Time)
• Participants: Investors and Financial Analysts
• Additional Details: To be published on company website

Regulatory Communication

Company Secretary and Compliance Officer Sampath Kumar Pallerlamudi signed the official communication sent to stock exchanges. The formal notification ensures compliance with Regulation 29 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, maintaining transparency standards for listed pharmaceutical companies.

Gland Pharma operates from its registered office in Hyderabad's Medchal-Malkajgiri District, with corporate headquarters located in Sangareddy District. The company maintains active communication channels through its official website at www.glandpharma.com , where stakeholders can access updated information about earnings calls and financial announcements.

Gland Pharma has received regulatory approval from the United States Food and Drug Administration (USFDA) for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, designated as an over-the-counter (OTC) medication. This approval marks a significant regulatory milestone for the pharmaceutical company in the US market.

Product Approval Details

The approved product represents an important addition to Gland Pharma's ophthalmic care portfolio in the United States. The following table outlines the key details of the regulatory approval:

Market Significance

The OTC classification of this ophthalmic solution allows consumers to purchase the product directly without requiring a prescription from healthcare providers. This regulatory status typically facilitates broader market access and consumer convenience, potentially contributing to increased product adoption in the competitive US eye care market.

Strategic Impact

This USFDA approval strengthens Gland Pharma's regulatory portfolio and expands its presence in the American pharmaceutical market. The approval demonstrates the company's capability to meet stringent US regulatory standards for ophthalmic products, reinforcing its position in the specialized eye care segment.

The addition of this OTC ophthalmic solution to Gland Pharma's approved product lineup enhances the company's ability to serve the US market with accessible eye care solutions.